



TEVA PHARMACEUTICAL INDUSTRIES LTD.

website: [www.tevapharm.com](http://www.tevapharm.com)


CONTACT INFORMATION:

**Liraz Kalif**  
**Investor Relations**  
**Teva Pharmaceutical Industries Ltd.**  
 Tel ++972-3-926-7281  
 Fax ++972-3-926-7519  
 E-mail: [liraz.kalif@teva.co.il](mailto:liraz.kalif@teva.co.il)

**Kevin Mannix**  
**Director, Investor Relations**  
**Teva North America**  
 Tel (215) 591-8912  
 Fax (215) 591-8803  
 E-mail: [kevin.mannix@tevausa.com](mailto:kevin.mannix@tevausa.com)


Net Sales

(U.S. \$ in millions)




Net Income<sup>(1)</sup>

(U.S. \$ in millions)




Earnings per ADR<sup>(1)(2)</sup>

(in U.S. \$)



Shareholders' Equity

(U.S. \$ in millions)



COMPANY OVERVIEW


Teva Pharmaceutical Industries Ltd. is one of the leading pharmaceutical companies in the world, specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. With operations in over 50 countries and approximately 25,000 employees worldwide, the Company offers the widest range of cost-effective pharmaceuticals, both generic and branded, to consumers, customers and healthcare providers. Teva differentiates itself by balancing its portfolio with generic and innovative activities, by the strategic depth of its vertical integration, by combining local customer responsiveness with a "global edge" and by successfully managing increasing profitable growth and complexity. Backed by over 100 years of experience in the pharmaceutical industry, Teva is not simply a leader but the clear bellwether in its business. Our success lies in the leadership of our management, the skills and devotion of our people, the quality of our offerings and our focus on customers and patients.

Market Data (as of November 3, 2006) **NASDAQ-100**

Stock Symbol	<b>TEVA</b>
Recent Price	\$32.40
52 week range	\$29.22 - \$45.91
Market Capitalization	\$26 billion
# 18 in NASDAQ-100	

In-Market Global Sales of Copaxone®

(U.S. \$ in millions)



(1) Before non-recurring items (after tax).

(2) Reflects the 2:1 stock splits (Dec. 2002, June 2004) and potential dilution of contingent convertible Debt.



TEVA PHARMACEUTICAL INDUSTRIES LTD.



## RECENT EVENTS

**November 7, 2006** - Teva reported its third quarter 2006 financial results. Q3 sales amounted to \$2,286 million (up 74%). Net income and EPS reached \$606 million (up 127%) and \$0.74 (up 85%) respectively.

**October 18, 2006** - Teva reported that Israel Makov, 67, has announced his plans to retire as President and CEO during the course of 2007. Shlomo Yanai, 55, will join the company as President and CEO Designate during the first part of 2007.

**September 29, 2006** - A new study showed that very active patients who received COPAXONE® (glatiramer acetate injection) therapy alone following short-term induction treatment with mitoxantrone experienced an 89 percent greater reduction (P<0.0001) compared to those receiving COPAXONE® alone, in Magnetic Resonance Imaging (MRI)-disease activity as measured by Gadolinium (Gd) enhancing lesions of the brain. This initial benefit achieved early on in the study was maintained over the entire 15-month study period. In addition, no adverse events outside of those associated with either treatment when used as monotherapy were observed.

**September 20, 2006** - Teva and Procognia (Israel) Ltd. announced that they had entered into a collaboration agreement covering two biopharmaceuticals, for which Procognia (Israel) Ltd. will supply Teva services and access to its proprietary glycoanalysis technology on an exclusive basis.

**September 5, 2006** - Teva and Active Biotech AB (ACTI.ST) announced that a Phase IIb study designed to evaluate the safety and efficacy of laquinimod, a once-daily novel oral agent, in relapsing remitting multiple sclerosis (MS) patients, met its primary end-point.

**August 29, 2006** - Teva announced that it has signed an agreement with The Purdue Frederick Company and certain of its affiliates to settle patent infringement litigation pertaining to Teva's generic version of Purdue's OxyContin® (oxycodone HCl extended-release) Tablets.

**August 21, 2006** - Teva announced that AZILECT® (rasagiline tablets), the first once daily oral treatment for Parkinson's disease (PD) has

just been approved by Health Canada. The drug is approved for use as initial monotherapy in early Parkinson's disease and as adjunct therapy to levodopa in moderate to advanced disease.

**August 14, 2006** - Teva announced that it has begun the sale of its generic version of Pfizer's Zoloft® (Sertraline) Tablets, 25 mg, 50 mg, and 100 mg in the United States. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

## U.S. Pipeline\* (as of October 24, 2006)

**145** ANDAs - Over **\$86** Billion In Total Sales

**44** First-To-File: Over **\$34** Billion In Total Sales


\* Including products under the agreement with Andrx and Impax

## Sales by Region

(U.S. \$ in billions)


### Q3 06: \$2.29 Billion

■ North America - 62%  
■ Europe\* - 23%  
■ International - 15%



### Q3 05: \$1.32 Billion

■ North America - 60%  
■ Europe\* - 29%  
■ International - 11%



\* Western Europe and Hungary

## FDA Approvals July 2006 - October 2006

Product		Approval / Launch Date	Branded Product		Indication
			Brand	market size (\$ millions)	
Risperdal®	Oral Solution	October 06	Risperidone	\$66	Indicated for treatment of schizophrenia and acute manic or mixed episodes associated with Bipolar I Disorder.
Venlafaxine Hydrochloride (1)	Tabs	August 06	Effexor®	\$152	Indicated for the treatment of major depressive disorder.
Sertraline (1)	Tabs	August 06	Zoloft®	\$3,099	Indicated for treatment of major depressive disorder.
Meloxicam (1)	Tabs	July 06	Mobic®	\$1,000	Indicated for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.
Amlodipine Besylate and Benazepril HCl (3)	Caps	July 06	Lotrel®	\$1,300	Hypertension treatment.

(1) Launched (2) Exclusivity (180 days) (3) Tentative approval